Welcome to our dedicated page for Monte Rosa Therapeutics SEC filings (Ticker: GLUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biotechnology company developing molecular glue degrader (MGD) medicines, Monte Rosa uses SEC reports to describe its clinical programs, collaborations, and financial condition.
Among the most informative documents for GLUE are current reports on Form 8-K, which the company uses to announce material events such as interim clinical data, financial results, and collaboration updates. For example, Monte Rosa has furnished 8-Ks summarizing positive interim Phase 1/2 data for MRT-2359 in metastatic castration-resistant prostate cancer and reporting quarterly financial results and business updates, including progress on MRT-8102, MRT-6160, and its partnerships with Novartis and Roche.
Investors can also reference Monte Rosa’s annual reports on Form 10-K and quarterly reports on Form 10-Q, which the company cites in its forward-looking statements as sources of detailed risk factors and operational information. These periodic filings typically include descriptions of the QuEEN™ discovery engine, the status of key programs such as MRT-8102, MRT-2359, and MRT-6160, and the structure of collaboration and license agreements.
On Stock Titan, GLUE filings are updated in near real time as they appear in the SEC’s EDGAR system. AI-powered tools help summarize lengthy documents, highlight key sections on clinical development, collaboration revenue, and cash runway, and make it easier to locate items on topics such as interim trial results, planned Phase 2 studies, or changes in capital structure. Users can quickly review Form 8-K disclosures about material events alongside the underlying press releases and presentations referenced in those filings.
Monte Rosa Therapeutics (common stock) filing a Schedule 13G/A (Amendment No. 2) reports beneficial ownership by Dimension-related entities and affiliated individuals. The cover pages show shared voting and dispositive power over 6,513,765 shares for several reporting persons and 5,663,265 and 850,500 shares held directly by Dimension Capital I and Dimension Capital II, respectively. The percentages use a baseline of 80,015,667 shares outstanding as of March 2, 2026.
GLUE filed a Form 144 notice reporting an intended sale of 18,683 shares of Common Stock via a stock option exercise, dated 04/16/2026.
The filing lists prior sales by the same holder during the past three months including 25,164 shares on 02/27/2026 and 26,117 shares on 04/08/2026.
Monte Rosa Therapeutics President & CEO Markus Warmuth reported an open-market sale of 8,000 shares of Common Stock. The sale occurred on April 14, 2026 at a weighted average price of $17.6406 per share, with individual trade prices ranging from $17.64 to $17.65. After this transaction, he directly holds 605,471 shares of Monte Rosa Therapeutics common stock, indicating he retains a substantial equity position in the company.
Markus Warmuth reported the sale of 5,466 shares of Common Stock under Rule 144. The sale is shown with a proceeds figure of $97,974.22 and relates to restricted shares originally dated 09/01/2020. The Form 144 lists 8,000 restricted shares associated with the issuer record.
Edmund Dunn reported proposed sales of Common Stock on Form 144 for GLUE. The filing lists multiple transactions, including 26,117 shares reported on 04/08/2026 for $450,622.72 and 25,164 shares reported on 02/27/2026 for $455,506.15. The excerpt also shows several stock option exercises dated 04/10/2026 with individual exercise quantities of 1,113; 13,350; 1,112; and 1,112 shares.
Monte Rosa Therapeutics’ Chief Business & Legal Officer, Nickson Philip, sold 5,845 shares of common stock in an open-market transaction. The sale on April 9, 2026 was executed at a weighted average price of $17.6925 per share, based on multiple trades within a narrow range. After this sale, he directly holds 55,000 shares of Monte Rosa Therapeutics common stock.
Edmund Dunn reported sales of Common Stock under Form 144. The filing lists 26,117 shares to be sold with a stock option exercise noted on 04/08/2026 and cash as the payment method. The filing also lists past sales of 25,164 shares (02/27/2026), 536 shares (03/02/2026), and 139 shares (03/04/2026) with the dollar amounts shown.
Monte Rosa Therapeutics, Inc. Principal Accounting Officer Matthew Bowen received new equity awards. He was granted a stock option covering 19,500 shares of common stock at an exercise price of $16.93 per share, expiring on April 5, 2036. Separately, he received 4,300 restricted stock units, each representing one share upon vesting. The RSUs vest 25% on April 6, 2027, with the remainder in three equal annual installments, while the option vests 25% on April 6, 2027 and then in 36 substantially equal monthly installments, in each case subject to continued service. Following the RSU grant, he directly owns 25,904 shares of common stock.
Monte Rosa Therapeutics, Inc. executive Matthew Bowen, Principal Accounting Officer, filed an initial ownership report showing direct holdings of common stock and multiple stock option awards. He reports 21,604 shares of common stock held directly, which includes 3,590 unvested restricted stock units that convert into shares as they vest.
Bowen also holds several stock options to buy common stock at exercise prices ranging from $5.71 to $23.99 per share, with expiration dates between 2031 and 2036. These options vest over time, often with 25% vesting on a stated date and the balance in 36 monthly installments, contingent on continued service.